All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›Samsung Asset Management›185680

185680

Samsung KODEX SYNTH-US Biotech ETF

Passive ETF Equity

Not rated

The 185680 Exchange Traded Fund (ETF) is provided by Samsung Asset Management. It is built to track an index: S&P Biotechnology Select Industry Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). This share class generates a stream of income by distributing dividends.

₩49,805

+₩275 (+0.56%) today

12:00 AM 07/15/26 Closed

1D price range

₩49,360₩49,995

52W price range

₩25,484.63₩52,750.98

YTD Perf.

+29.36%

YTD Flows

Annualized volatility

Fund AuM

€16M

Share class AuM

€16M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

KR7185680006

TER

0.25%

Inception date

10/30/2013

Issuer

Samsung Asset Management

Benchmark

S&P Biotechnology Select Industry Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

No content available for this fund

API

PerformanceDec 30, 2025 - Jul 14, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

99.41%

Unavailable

0.21%

Other

0.33%

Latest 185680 news

No content available for this fund

FAQ about 185680

185680 is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.

185680 tracks the S&P Biotechnology Select Industry Index - USD, through a replication method.

185680 carries a total expense ratio (TER) of 0.25%, indicating the annual cost for holding the fund.

185680 was introduced to the market on October 30, 2013. It trades on South Korea

Samsung KODEX SYNTH-US Biotech ETF, 185680, is provided by Samsung Asset Management. Learn more about Samsung Asset Management here.

185680 oversees €16M in assets as of July 14, 2026.

185680 follows a distributing dividend policy, meaning it pays out income to investors.

As of May 31, 2026, 185680 has significant geographic allocations in USA, Ireland and Switzerland.

As of May 31, 2026, 185680 focuses largely on Healthcare.

As of May 31, 2026, 185680 holds 146 positions in its portfolio, with 21.98% of assets concentrated in its top 15 holdings.

As of May 31, 2026, 185680 top three holdings include Travere Therapeutics, Inc., Revolution Medicines, Inc. and Alkermes Plc.

The base currency of 185680 is KRW.

Top 10 holdings

Data as of 05/31/26

Travere Therapeutics, Inc.

1.79%

Revolution Medicines, Inc.

1.78%

Alkermes Plc

1.71%

Twist Bioscience Corp.

1.60%

TG Therapeutics, Inc.

1.52%

Arrowhead Pharmaceuticals, Inc.

1.51%

Beam Therapeutics, Inc.

1.42%

Neurocrine Biosciences, Inc.

1.37%

Krystal Biotech, Inc.

1.36%

Exelixis, Inc.

1.36%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

Samsung KODEX SYNTH-US Biotech ETF

FAQ about 185680

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US